Curis Provides Updated Data from its Frontline AML Triplet Study

Core Insights - Curis, Inc. presented updated clinical data for emavusertib in an ongoing study for Acute Myeloid Leukemia (AML), showing that 5 of 8 patients (62.5%) achieved Undetectable Minimal Residual Disease (uMRD) [1][3]. Study Overview - The AML triplet study evaluates the efficacy of adding emavusertib to a treatment regimen of venetoclax and azacitidine for AML patients who are MRD-positive after achieving complete remission [2]. - The study's initial data indicated that 4 of 8 patients (50%) achieved uMRD as of July 2, 2025, which improved to 5 of 8 patients (62.5%) by October 12, 2025, with no changes in safety profile [3]. Executive Commentary - The CEO of Curis, James Dentzer, expressed optimism about the data, suggesting further evaluation of additional triplet regimens to optimize dosing and scheduling for better patient outcomes in challenging cases [4]. Company Background - Curis, Inc. focuses on developing emavusertib, an orally available small molecule IRAK4 and FLT3 inhibitor, currently being tested in various studies for different hematological malignancies [5]. - Emavusertib has received Orphan Drug Designation from the FDA for treating conditions like PCNSL, AML, and MDS, indicating its potential significance in addressing unmet medical needs [5].